IntronBio Announces Cash Dividend and Treasury Stock Cancellation Plan

Intron Bio announced its plans for cash dividends and treasury stock cancellation on the 12th.

Shareholders as of the 31st will receive a cash dividend of 100 KRW per share. Additionally, approximately 960,000 shares of treasury stock will be canceled.

Yoon Kyung-won, CEO of Intron Bio, explained, "The announcement of the cash dividend and treasury stock cancellation plan is a proactive response to the decline in stock price due to external circumstances." He added, "We are fully committed to research and development (R&D) and management as planned," emphasizing, "This is to highlight that there are no issues either operationally or financially."

CEO Yoon stated, "Along with the technology export of SAL200, we generated significant profits from the diagnostic kit business during the recent COVID-19 pandemic," and added, "We have secured high financial stability with a debt ratio of about 1.7%."

He continued, "Intron Bio, as a 'new drug development company,' focused on fundamental R&BD investments this year," and introduced, "We believe we have established multiple platform capabilities and will begin full-scale commercialization starting next year."

Based on stable financial indicators, Intron Bio appears to be engaging in various shareholder return policies to appease its shareholders.

This content was produced with the assistance of AI translation services.